Edesa Biotech (NASDAQ: EDSA) major holder's multi-million-share stake detailed

Rhea-AI Filing Summary

Edesa Biotech, Inc. (EDSA) received an amended Schedule 13D (Amendment No. 11) from Dr. Pardeep Nijhawan and related entities updating their beneficial ownership in the company’s common shares.

Dr. Nijhawan is reported as the beneficial owner of 2,613,492 common shares, representing approximately 16.31% of Edesa’s outstanding common shares, including shares held directly, through options, restricted share units, warrants, and preferred shares, as well as through several Ontario entities and a family trust. The filing is based on 14,193,356 common shares outstanding as of August 25, 2026, plus specified derivative securities deemed outstanding for this holder. The amendment also notes that since the prior amendment, Dr. Nijhawan received 3,378 restricted share units on July 2, 2026 and 5,324 restricted share units on August 3, 2026, each vesting in full upon grant and issued in lieu of partial salary.

Key Figures

Total beneficial ownership – Dr. Pardeep Nijhawan: 2,613,492 common shares Ownership percentage – Dr. Pardeep Nijhawan: 16.31 % Shares outstanding – Edesa common shares: 14,193,356 common shares +5 more

8 metrics

Total beneficial ownership – Dr. Pardeep Nijhawan 2,613,492 common shares Aggregate beneficial ownership of Edesa Biotech as of August 25, 2026

Ownership percentage – Dr. Pardeep Nijhawan 16.31 % Percent of Edesa Biotech outstanding common shares deemed beneficially owned

Shares outstanding – Edesa common shares 14,193,356 common shares Common shares outstanding as of August 25, 2026

Beneficial ownership – Pardeep Nijhawan Medicine Professional Corporation 1,164,676 common shares Includes common shares, vested warrants and Series A-1 Preferred Shares

RSUs granted July 2, 2026 3,378 restricted share units Granted to Dr. Nijhawan, vested in full upon grant, in lieu of partial salary

RSUs granted August 3, 2026 5,324 restricted share units Granted to Dr. Nijhawan, vested in full upon grant, in lieu of partial salary

Options included in Nijhawan ownership 56,875 common shares Shares underlying vested options or options vesting within 60 days of August 25, 2026

RSUs included in Nijhawan ownership 491,288 common shares Shares underlying vested RSUs or RSUs vesting within 60 days of August 25, 2026

Key Terms

beneficial owner, restricted share units, Series A-1 Preferred Shares, Series B-1 Preferred Shares, +1 more

5 terms

beneficial owner financial

"may be deemed to be the beneficial owner of an aggregate of 2,613,492"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

restricted share units financial

"56,875 Common Shares underlying vested share options or underlying share"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

Series A-1 Preferred Shares financial

"435,414 Common Shares underlying Series A-1 Preferred Shares that are deemed"

Series B-1 Preferred Shares financial

"520,833 Common Shares underlying Series B-1 Preferred Shares that are"

A Series B‑1 preferred share is a specific subclass of preferred stock created during a financing round that gives its holders rights ahead of ordinary shareholders, such as priority on dividends and first claim on proceeds if the company is sold or shuts down. For investors it matters because these shares change how returns and control are allocated—think of them as a reserved, front‑of‑the‑line ticket that reduces downside risk and can include options to convert into common stock or extra voting power.

Schedule 13D regulatory

"This Amendment No. 11 ("Amendment No. 11") amends and supplements the statement on"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

FAQ

What percentage of Edesa Biotech, Inc. (EDSA) does Dr. Pardeep Nijhawan beneficially own according to this Schedule 13D/A?

Dr. Pardeep Nijhawan is reported as the beneficial owner of 2,613,492 common shares of Edesa Biotech, Inc., representing approximately 16.31% of the issuer’s outstanding common shares, including shares held directly, through derivatives, and via affiliated entities and a family trust.

How many Edesa Biotech (EDSA) shares is Pardeep Nijhawan Medicine Professional Corporation reported to beneficially own?

Pardeep Nijhawan Medicine Professional Corporation may be deemed to beneficially own 1,164,676 Edesa Biotech common shares, representing approximately 7.8% of the issuer’s outstanding common shares, including 402,702 common shares, 326,560 shares underlying vested warrants and 435,414 shares underlying Series A-1 Preferred Shares.

What is the total number of Edesa Biotech (EDSA) common shares outstanding used in the ownership calculations?

The ownership percentages in this Schedule 13D/A are calculated using 14,193,356 Edesa Biotech common shares outstanding as of August 25, 2026, plus specified options, restricted share units, warrants and preferred shares deemed outstanding for the relevant reporting persons.

What recent equity compensation did Dr. Pardeep Nijhawan receive from Edesa Biotech (EDSA)?

Since the prior amendment, Edesa Biotech granted Dr. Pardeep Nijhawan 3,378 restricted share units on July 2, 2026 and 5,324 restricted share units on August 3, 2026. These grants vested in full upon grant and were issued in lieu of partial salary.

How much of Edesa Biotech (EDSA) does The Digestive Health Clinic Inc. beneficially own?

The Digestive Health Clinic Inc. may be deemed to beneficially own 32,013 Edesa Biotech common shares, representing approximately 0.2% of the company’s outstanding common shares, based on 14,193,356 common shares outstanding as of August 25, 2026.

What are the key derivative securities included in Dr. Nijhawan’s Edesa Biotech (EDSA) beneficial ownership?

Dr. Nijhawan’s beneficial ownership includes 56,875 shares underlying vested or soon-vesting options, 491,288 shares underlying vested or soon-vesting restricted share units, 326,560 shares underlying vested warrants, 435,414 shares underlying Series A-1 Preferred Shares, and 520,833 shares underlying Series B-1 Preferred Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 06:01 PM Accepted by SEC EDGAR 08/25/2026 - 06:00 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 11)

EDESA BIOTECH, INC.

(Name of Issuer)

Common Shares, no par value per share

(Title of Class of Securities)

27966L306

(CUSIP Number)

Dr. Pardeep Nijhawan
c/o Edesa Biotech, Inc., 100 Spy Court,
Markham, A6, L3R 5H6
(289) 800-9600

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/21/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 27966L306

1

Name of reporting person

Pardeep Nijhawan Medicine Professional Corporation

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,164,676.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,164,676.00

11

Aggregate amount beneficially owned by each reporting person

1,164,676.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.8 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

For box 13, based on a total of 14,193,356 Common Shares of the Company outstanding as of August 25, 2026, and an additional 326,560 Common Shares underlying vested warrants and an additional 435,414 Common Shares underlying Series A-1 Preferred Shares that are deemed outstanding with respect to this Reporting Person.

SCHEDULE 13D

CUSIP Number(s): 27966L306

1

Name of reporting person

The Digestive Health Clinic Inc.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 32,013.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 32,013.00

11

Aggregate amount beneficially owned by each reporting person

32,013.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

For box 13, based on a total of 14,193,356 Common Shares of the Company outstanding as of August 25, 2026.

SCHEDULE 13D

CUSIP Number(s): 27966L306

1

Name of reporting person

1968160 Ontario Inc.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 53,104.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 53,104.00

11

Aggregate amount beneficially owned by each reporting person

53,104.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.4 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

For box 13, based on a total of 14,193,356 Common Shares of the Company outstanding as of August 25, 2026.

SCHEDULE 13D

CUSIP Number(s): 27966L306

1

Name of reporting person

The New Nijhawan Family Trust 2015

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 32,609.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 32,609.00

11

Aggregate amount beneficially owned by each reporting person

32,609.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

For box 13, based on a total of 14,193,356 Common Shares of the Company outstanding as of August 25, 2026.

SCHEDULE 13D

CUSIP Number(s): 27966L306

1

Name of reporting person

Pardeep Nijhawan

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF, PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,331,090.00
8	Shared Voting Power 1,282,402.00
9	Sole Dispositive Power 1,331,090.00
10	Shared Dispositive Power 1,282,402.00

11

Aggregate amount beneficially owned by each reporting person

2,613,492.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

16.31 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Boxes 8 and 10, consists of 1,164,676 Common Shares beneficially owned by Pardeep Nijhawan Medicine Professional Corporation, 32,013 Common Shares beneficially owned by The Digestive Health Clinic Inc., 53,104 Common Shares beneficially owned by 1968160 Ontario Inc. and 32,609 Common Shares beneficially owned by The New Nijhawan Family Trust 2015. For box 13, based on a total of 14,193,356 Common Shares of the Company outstanding as of August 25, 2026, an additional 56,875 Common Shares underlying vested share options or underlying share options that will vest within 60 days of August 25, 2026, an additional 491,288 Common Shares underlying vested restricted share units or restricted share units that will vest within 60 days of August 25, 2026, an additional 326,560 Common Shares underlying vested warrants, an additional 435,414 Common Shares underlying Series A-1 Preferred Shares and an additional 520,833 Common Shares underlying Series B-1 Preferred Shares that are beneficially owned and deemed outstanding with respect to this Reporting Person.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Shares, no par value per share
(b)	Name of Issuer: EDESA BIOTECH, INC.
(c)	Address of Issuer's Principal Executive Offices: 100 Spy Court, Markham, ONTARIO, CANADA , L3R 5H6.
Item 1 Comment: This Amendment No. 11 ("Amendment No. 11") amends and supplements the statement on Schedule 13D jointly filed by (i) Pardeep Nijhawan Medicine Professional Corporation, formed in Ontario, Canada, (ii) The Digestive Health Clinic Inc., formed in Ontario, Canada, (iii) 1968160 Ontario Inc., an Ontario, Canada corporation (iv) The New Nijhawan Family Trust 2015, an Ontario, Canada trust and (v) Dr. Pardeep Nijhawan, an individual on June 17, 2019, as amended by Amendment No. 1 filed on August 19, 2019, as further amended by Amendment No. 2 filed on January 16, 2020, as further amended by Amendment No. 3 filed on September 18, 2020, as further amended by Amendment No. 4 filed on November 8, 2022, as further amended by Amendment No. 5 filed on August 21, 2023, as further amended by Amendment No. 6 filed on January 16, 2024, as further amended by Amendment No. 7 filed on November 1, 2024, as further amended by Amendment No. 8 filed on February 14, 2025, as further amended by Amendment No. 9 filed on March 2, 2026, as further amended by Amendment No. 10 filed on June 16, 2026 (as so amended and supplemented, the "Schedule 13D"), with respect to the common shares, no par value per share (the "Common Shares") of Edesa Biotech, Inc., a British Columbia corporation (the "Company" or the "Issuer"). Except as expressly amended by this Amendment No. 11, the Schedule 13D remains in full force and effect. The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 is hereby supplemented as follows: Since the filing of the Schedule 13D/A on June 16, 2026, the Issuer has granted Dr. Pardeep Nijhawan the following restricted stock units, which vested in full upon grant: (i) 3,378 restricted share units on July 2, 2026 and (ii) 5,324 restricted share units on August 3, 2026. Such restricted share units were granted in lieu of partial salary.
Item 5.	Interest in Securities of the Issuer
(a)	As of the date hereof, Pardeep Nijhawan may be deemed to be the beneficial owner of an aggregate of 2,613,492 Common Shares, comprised of: (i) sole voting and dispositive power of 1,331,090 Common Shares, comprised of: (a) 262,094 Common Shares, (b) 491,288 Common Shares underlying vested restricted share units or restricted share units that will vest within 60 days of August 25, 2026, (c) 56,875 Common Shares underlying vested share options or underlying share options that will vest within 60 days of August 25, 2026 and (d) 520,833 Common Shares underlying Series B-1 Preferred Shares that are beneficially owned and deemed outstanding with respect to this Reporting Person; and (ii) shared voting and dispositive power of 1,282,402 Common Shares, comprised of: (a) 402,702 Common Shares, an additional 326,560 Common Shares underlying vested warrants and 435,414 Common Shares underlying Series A-1 Preferred Shares that are deemed outstanding held by Pardeep Nijhawan Medicine Professional Corporation, (b) 32,013 Common Shares held by The Digestive Health Clinic Inc., (c) 53,104 Common Shares held by 1968160 Ontario Inc., and (d) 32,609 Common Shares held by The New Nijhawan Family Trust 2015. Pardeep Nijhawan's holdings exclude Common Shares underlying restricted share units held by this Reporting Person that will not vest within 60 days of August 25, 2026 and Common Shares underlying share options held by this Reporting Person that will not vest within 60 days of August 25, 2026. Pardeep Nijhawan's holdings represent an aggregate of approximately 16.31% of the Issuer's outstanding Common Shares (based on a total of 14,193,356 Common Shares of the Issuer outstanding as of August 25, 2026, 56,875 Common Shares underlying vested share options or underlying share options that will vest within 60 days of August 25, 2026, 491,288 Common Shares underlying vested restricted share units or restricted share units that will vest within 60 days of August 25, 2026, 326,560 Common Shares underlying vested warrants, 435,414 Common Shares underlying Series A-1 Preferred Shares and 520,833 Common Shares underlying Series B-1 Preferred Shares that are beneficially owned and deemed outstanding with respect to this Reporting Person). As of the date hereof, Pardeep Nijhawan Medicine Professional Corporation may be deemed to be the beneficial owner, with shared voting and dispositive power, of an aggregate of 1,164,676 Common Shares, comprised of: (i) 402,702 Common Shares, (ii) 326,560 Common Shares underlying vested warrants and (iii) 435,414 Common Shares underlying Series A-1 Preferred Shares that are deemed outstanding with respect to this Reporting Person. Pardeep Nijhawan Medicine Professional Corporation's holdings represent an aggregate of approximately 7.8% of the Issuer's outstanding Common Shares (based on a total of 14,193,356 Common Shares of the Issuer outstanding as of August 25, 2026, 326,560 Common Shares underlying vested warrants and 435,414 Common Shares underlying Series A-1 Preferred Shares that are deemed outstanding with respect to this Reporting Person). As of the date hereof, The Digestive Health Clinic Inc. may be deemed to be the beneficial owner, with shared voting and dispositive power, of 32,013 Common Shares, representing an aggregate of approximately 0.2% of the Issuer's outstanding Common Shares (based on a total of 14,193,356 Common Shares of the Issuer outstanding as of August 25, 2026). As of the date hereof, 1968160 Ontario Inc. may be deemed to be the beneficial owner, with shared voting and dispositive power, of 53,104 Common Shares, representing an aggregate of approximately 0.4% of the Issuer's outstanding Common Shares (based on a total of 14,193,356 Common Shares of the Issuer outstanding as of August 25, 2026). As of the date hereof, The New Nijhawan Family Trust 2015 may be deemed to be the beneficial owner, with shared voting and dispositive power, of 32,609 Common Shares, representing an aggregate of approximately 0.2% of the Issuer's outstanding Common Shares (based on a total of 14,193,356 Common Shares of the Issuer outstanding as of August 25, 2026).
(b)	The information contained in Item 5(a) of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 5(b).
(c)	Except as set forth in this Schedule 13D, the Reporting Persons have not effected any transactions with respect to the Common Shares of the Issuer during the past 60 days.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Pardeep Nijhawan Medicine Professional Corporation

Signature:	/s/ Pardeep Nijhawan
Name/Title:	Pardeep Nijhawan, Chief Executive Officer
Date:	08/25/2026

The Digestive Health Clinic Inc.

Signature:	/s/ Pardeep Nijhawan
Name/Title:	Pardeep Nijhawan, Chief Executive Officer
Date:	08/25/2026

1968160 Ontario Inc.

Signature:	/s/ Pardeep Nijhawan
Name/Title:	Pardeep Nijhawan, Chief Executive Officer
Date:	08/25/2026

The New Nijhawan Family Trust 2015

Signature:	/s/ Pardeep Nijhawan
Name/Title:	Pardeep Nijhawan, Trustee
Date:	08/25/2026

Pardeep Nijhawan

Signature:	/s/ Pardeep Nijhawan
Name/Title:	Pardeep Nijhawan
Date:	08/25/2026